Seattle Genetics Inc.

Eric Dobmeier joined Seattle Genetics in March 2002. He manages the company's business development, legal, corporate communications, strategic marketing and project management groups. While at Seattle Genetics, he has led negotiation and completion of multiple corporate alliances, including the worldwide license agreement with Genentech on SGN-40, the in-license of SGN-33 from PDL BioPharma and ADC collaborations with CuraGen, Progenics, Bayer, MedImmune and Agensys. He has also participated in raising over $200 million in equity financing for Seattle Genetics. Prior to joining the company, Mr. Dobmeier was with the law firms of Venture Law Group and Heller Ehrman White & McAuliffe, where he represented technology companies in connection with public and private financings, mergers & acquisitions and corporate partnering transactions. Mr. Dobmeier holds a law degree from Boalt Hall School of Law, University of California, Berkeley and an undergraduate degree from Princeton University.

Morris Rosenberg joined Seattle Genetics in July 2001. Prior to joining the company, he was with Eli Lilly & Company (1998-2001), Biogen Incorporated (1990-1998) and Invitron Corporation (1987-1990). Dr. Rosenberg received a D.Sc. in Chemical Engineering, an M.S. and B.S. in Chemical Engineering, and a B.A. in Biology from Washington University in St. Louis, Missouri. While at Biogen he participated in the development of the manufacturing process for the multiple sclerosis treatment Avonex. Most recently at Eli Lilly, as Head of Cell Culture and Fermentation Development, Dr. Rosenberg led efforts in the development of several cell culture processes including for the sepsis therapeutic Xigris.

Vaughn Himes joined Seattle Genetics in April 2009, bringing more than twenty years of experience in manufacturing, technical operations, process development and scale-up activities. As Executive Vice President, Technical Operations, he oversees Seattle Genetics' manufacturing, supply chain and quality assurance and control functions. Previously, Dr. Himes was with Zymogenetics, Inc., most recently as Senior Vice President, Technical Operations where his responsibilities included commercial and clinical manufacturing, supply chain and logistics, quality control and process development. While at Zymogenetics, he oversaw the chemistry, manufacturing and control (CMC) portion of the successful Biologics License Application for Recothrom and managed its commercial supply. Previously, he held Vice President positions in manufacturing and development at Corixa, Targeted Genetics and Genovo. Dr. Himes received a Bachelor of Arts in Chemistry from Pomona College in California and a Ph.D. in Chemical Engineering from the University of Minnesota.

Christopher Pawlowicz joined Seattle Genetics in September 2008. He has more than 25 years of human resources experience principally in the pharmaceutical industry. Prior to Seattle Genetics, Mr. Pawlowicz was Senior Vice President, Human Resources and Administration at MedPointe Pharmaceuticals, a private equity-backed specialty pharma company where he was part of the turnaround team that successfully restructured and sold the business to Meda Pharmaceuticals. Before that, he was Corporate Vice President, Human Resources at Express Scripts, the nation's third largest pharmacy benefit management company. Mr. Pawlowicz's career has also included senior human resources positions at Pharmacia, Searle and Monsanto. Highlights include the global launch of Celebrex, the start up of biotechnology commercial teams in plant sciences, support of high growth commercial investments in Latin America, Europe and Asia, and the post-merger integration of numerous companies. He graduated summa cum laude with a B.A. in Economics from Benedictine College, and received his M.A., Labor and Industrial Relations from the University of Illinois Urbana-Champaign.

Array

Eric Sievers joined Seattle Genetics in July 2006. He is responsible for directing, planning and executing clinical development activities of several of the company’s therapeutic programs. From 2003 to 2006, Dr. Sievers served as Medical Director at Zymogenetics supervising the oncology development of interleukin-21 and Atacicept. He performed his training in pediatric hematology and oncology at the University of Washington and the Fred Hutchinson Cancer Research Center, and served on the faculty of both institutions for over a decade. His academic research focused on improving treatment outcomes for patients with acute myeloid leukemia by defining the safety and efficacy of gemtuzumab ozogamicin (Mylotarg®) and evaluating novel flow cytometric techniques to predict leukemic recurrence. He is a member of the American Society of Hematology, American Society of Clinical Oncology and American Association for Cancer Research and is certified by the American Board of Pediatrics.

Dr. Felix J. Baker has served as a director of Neurogen Corporation since May 1999. Dr. Baker is a Managing Member of Baker Bros. Advisors, LLC, which he and his brother, Julian Baker, founded in 2000. Dr. Baker's firm manages Baker Brothers Investments, a family of long-term investment funds for major university endowments and foundations, which are focused on publicly traded life sciences companies. Dr. Baker's career as a fund-manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family. Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. He is also a director of Conjuchem Inc., Seattle Genetics, Inc., and Trimeris, Inc.

Franklin M. Berger, CFA, has served as a Director of Seattle Genetics since June 2004 and is Chairman of the Audit Committee. Mr. Berger is a biotechnology industry analyst with over 25 years of experience in capital markets and financial analysis. He served most recently as Managing Director, Equity Research and Senior Biotechnology Analyst at J.P. Morgan Securities from 1998 to 2003. In this position, he initiated team coverage of 26 biotechnology companies and was responsible for technical, scientific and clinical due diligence as well as company selection. Previously, Mr. Berger served in similar capacities at Salomon Smith Barney from 1997 to 1998 and Josephthal & Co. from 1991 to 1997. Prior to his work as a biotechnology analyst, he managed Pantagruel Partners, a firm that developed early-stage pharmaceutical compounds for sale to drug companies and venture capital firms. He holds an M.B.A. from the Harvard Graduate School of Business Administration and an M.A. in International Economics and a B.A. in International Relations both from Johns Hopkins University. In addition to Seattle Genetics, Mr. Berger serves as a director of VaxGen, Inc., Isotechnika Inc. and Thallion Pharmaceuticals, all publicly-traded biopharmaceutical companies, and HealthShares, Inc., an investment company.

Bruce R. Blazar, M.D., has served in various academic positions at the University of Minnesota since 1978. Presently, he is a Professor in the Division of Pediatric Bone Marrow Transplantation, Director, Cytokine Reference Laboratory, Associate Director, Division of Pediatric Bone Marrow Transplantation and Andersen Chair in Transplantation Immunology. Dr. Blazar has received numerous professional honors and awards, including the American Cancer Society Clinical Fellowship Award, the NIH-NCI National Research Service Award and the MERIT Award. In addition to his past and present work on numerous editorial boards, he is a member of the FDA Advisory Committee on Biological Response Modifiers and the Leukemia and Lymphoma Society Translational Research Grant Committee. Dr. Blazar received a B.S. in biology at the Renssalear Polytechnic Institute and completed medical school in 1978 at Albany Medical College. He has multiple active grants that support a substantial research effort and has published over 230 manuscripts.

Mr. Welch has served as Chairman, Chief Executive Officer and President of the company and a member of the Board since May 2008, and as President and Chief Executive Officer of the company and a member of the Board since September 2003. From March 2003 to September 2003, Mr. Welch served as a consultant to Warburg Pincus LLC, a global private equity investment firm. From August 2002 to January 2003, Mr. Welch served as chairman and chief executive officer of Triangle Pharmaceuticals, Inc., a pharmaceutical company. From October 2000 to June 2002, Mr. Welch served as president of the pharmaceutical division of Elan Corporation, PLC. From September 1987 to August 2000, Mr. Welch served in various senior management roles at Sanofi (now Sanofi-Aventis) and its predecessor companies Sanofi and Sterling Winthrop. During his time at Sanofi-Aventis, he led the successful worldwide launches of Plavix®, Eloxatin® and Avapro® as Vice President of Worldwide Marketing and he served as COO of the U.S. business. From November 1980 to September 1987, Mr. Welch was with American Critical Care, a division of American Hospital Supply. Mr. Welch holds a B.S. from the University of Miami and an M.B.A. from the University of North Carolina.

Douglas E. Williams, Ph.D., age 51, has served as one of our directors and Chief Executive Officer since January 2009. Previously, Dr. Williams served as our President and Chief Scientific Officer from July 2007 to January 2009 and as our Executive Vice President, Research and Development and Chief Scientific Officer from November 2004 to July 2007. From September 2003 to August 2004, Dr. Williams served as Chief Scientific Officer and Executive Vice President, Research and Development of Seattle Genetics, Inc., a biotechnology company. From November 2002 to August 2003, he was Head of Health and Strategic Development of Genesis Research & Development Corporation, LTD, a New Zealand biotechnology company. From July 2002 to October 2002, Dr. Williams served as Senior Vice President and Washington Site Leader of Amgen, Inc., a biotechnology company. From October 1999 to July 2002, he served as Executive Vice President and Chief Technology Officer at Immunex Corporation, a biotechnology company that was acquired by Amgen in 2002, and served as Senior Vice President of Discovery Research at Immunex from October 1994 to October 1999. Dr. Williams serves as a director of Anadys Pharmaceuticals, Inc., Array BioPharma Inc. and Aerovance, Inc. Dr. Williams also serves on the scientific advisory board of Symphony Capital. Dr. Williams received a B.S. (magna cum laude) in Biological Sciences from the University of Massachusetts, Lowell and a Ph.D. in Physiology from the State University of New York at Buffalo, Roswell Park Cancer Institute Division.

Marc Estes Lippman, M.D. lippmanm@umich.edu has been a senior advisor to Perseus for ten years and will devote up to 15% of his time to working with Perseus on biotechnology strategy. Dr. Lippman is the John G. Searle Professor and Chief of Medicine at the University of Michigan Health System. Prior to his current appointments, Dr. Lippman held a number of positions at Georgetown University Medical Center, including Director of the Lombardi Cancer Research Center, Professor and Chairman of the Department of Oncology, Professor of Medicine, and Chief of the Division of Hematology-Oncology. He also served as Head of the Medical Breast Cancer Section of the Medicine Branch of the National Cancer Institute.

William J. Murphy, Ph.D., is a Professor in the Microbiology and Immunology department at the University of Nevada School of Medicine in Reno. His research is focused on examining means to improve the efficacy of bone marrow transplantation (BMT) in cancer and other diseases. In addition, his laboratory has been examining BMT as a means to understand the immune system and the process of aging as well as on improving immune resistance to opportunistic infections that can arise after a transplant. Dr. Murphy is also the Director of Basic Research of the newly established Nevada Cancer Institute in Las Vegas and is a Guest Researcher at the National Cancer Institute, where he also maintains a laboratory. Dr. Murphy earned his B.S. in Biology at Rutgers University followed by his Ph.D. in Immunology from the University of Texas Southwestern Medical School in 1989. He did a post-doctoral fellowship under Dr. Dan Longo, then Director of the Biological Response Modifiers Program at the National Cancer Institute (NCI) at Frederick. He became Principal Investigator and Section Head of the Transplantation Biology Laboratory in 1996. In 2000, he became Director of Basic Research of SAIC Frederick at the NCI with a directorate consisting of over 250 scientific personnel and an operating budget of over 30 million dollars. In 2002, Dr. Murphy joined the University of Nevada. He was awarded the American Cancer Society Scholar Award for his research on immunotherapy and BMT in 2002. He currently serves on the editorial boards for Blood, Experimental Hematology, Clinical Immunology, and Biology of Blood and Bone Marrow Transplantation. He also is an ad-hoc member of several study sections at NIH. He is Honorary Scientific Director of the Shandong Cancer Biotherapy Center in P.R. China as well as Honorary Research Professor at the Institute of Biomedical Sciences. He has published over 160 articles in scientific journals and holds several patents concerning immunotherapy in cancer.